Emerging drug target in pancreatic cancer: placing Sirtuin 1 on the sanvas
Sirtuin 1 is a protein deacetylase that regulates a large number of proteins often functionally implicated in tumor development and progression. Its pleiotropic function has turned SIRT1 into an attractive chemotherapeutic target, underscored by very promising preclinical results with SIRT1 inhibitors in the treatment of chronic myeloid leukemia. Here, we revisit the studies on SIRT1 as an emerging target for therapy in pancreatic cancer, a tumor with dismal outcomes for which currently few therapeutic options are available. We highlight those potential SIRT1 target genes that are commonly affected in pancreatic cancer according to recent genomic analyses.
|Authors||Giry-Laterriere, M.; Pinho, A. V.; Eling, N.; Chantrill, L.; Rooman, I.|
|Publisher Name||CURRENT CANCER DRUG TARGETS|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/26282546|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/12905|